Bolt Biotherapeutics Extends Cash Runway into 2027, Reports Initial Positive Immune Response for BDC-4182
Summary
Bolt Biotherapeutics reported its fourth quarter and full-year 2025 financial results, highlighting a cash position of $31.8 million as of December 31, 2025, which is expected to fund operations into 2027. This extended cash runway is a critical positive for the micro-cap biopharmaceutical company. The company also provided a business update, noting a clear difference in immune response from the first patient treated with its next-generation Boltbody™ ISAC, BDC-4182, which is currently in a Phase 1 dose-escalation trial for gastric and gastroesophageal cancers. Initial clinical data for BDC-4182 is anticipated in the third quarter of 2026. However, two other preclinical ISAC programs targeting CEA and PD-L1 are currently on hold pending partnering or funding, indicating potential pipeline constraints. Traders will be watching for the BDC-4182 data readout and any developments regarding the preclinical programs.
At the time of this announcement, BOLT was trading at $4.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8M. The 52-week trading range was $4.01 to $9.66. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.